CYP2J2

Across TCGA pan-cancer cohorts, CYP2J2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP2J2 data layer compared with 19 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CYP2J2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYP2J2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, LUSC, and UCEC are the cancer types where CYP2J2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.117	0.703	<.001	36	view →
LUSC	DFS	Median	All	0.079	0.792	<.001	18	view →
UCEC	DFS	Median	All	1.000	0.628	.021	18	view →
SARC	DFS	Median	All	0.094	0.632	<.001	6	view →
LIHC	DFS	Median	All	0.096	0.526	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP2J2–ESCA (OS)

Open the ESCA breakdown →